Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER study of pemafibrate in primary biliary cholangitis with dyslipidemia and inadequate response to ursodeoxycholic acid
jRCTs031250778Recruiting
- Sponsor
- Kowa Company, Ltd.
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of pemafibrate in primary biliary cholangitis (PBC) and dyslipidemia, sponsored by Kowa Company, Ltd. Primary endpoint: Proportion of patients achieving improvement in ALP and gamma GTP after 12 months. Started Jul 2026; status: recruiting.
02
Drugs
pemafibrate
03
Conditions
primary biliary cholangitis (PBC)dyslipidemia
Beyond the preview
Go deeper on jRCTs031250778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250778.